Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review
Diagnostics · 16.08.2024 · 14 (16) · 1794
DOI: 10.3390/diagnostics14161794 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 16.08.2024. Verfasst von Demis N Lipe und 9 weiteren Autor:innen. Beteiligte Einrichtung: ProPharma Group, Raleigh, NC 27601, USA. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, The University of Texas MD Anderson Cancer Center, NIH HHS.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have significantly transformed cancer treatment, but their use is linked to immune-related adverse events (irAEs), including the rare ICI-associated myocarditis, myositis, and myasthenia gravis (MMM) overlap syndrome. This systematic review aims to highlight MMM’s clinical implications in emergency departments. PubMed and Embase were searched using a specific search strategy. Reports were eligible for inclusion if all three conditions were present and associated with the use of an ICI. Data were extracted by independent reviewers using the Rayyan web application for systematic reviews. Descriptive statistics and qualitative synthesis were used to summarize demographic, clinical, and treatment data for the reported cases. Among 50 cases, predominantly associated with melanoma, lung cancer, and renal cancer, the in-hospital mortality rate was 38.0%. The most commonly presenting symptoms were ptosis (58%), dyspnea (48%), diplopia (42%), or myalgia (36%). The median time from ICI initiation to MMM presentation was 21 days (interquartile range: 15–28 days). Corticosteroids were the primary treatment for the irAEs. MMM, a rare but potentially fatal complication of ICI therapy, requires prompt recognition in emergency settings. Corticosteroids should be initiated if suspected, without waiting for confirmation. Multidisciplinary collaboration is vital for diagnosis and treatment planning. Research on MMM’s link to specific cancers and ICIs is imperative for better risk assessment and interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ProPharma Group, Raleigh, NC 27601, USA.
- Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Cardiology, HCA Houston Kingwood, College of Medicine, University of Houston, Kingwood, TX 77339, USA.
- Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
ORCID-Profile: Demis N Lipe, Aiham Qdaisat, Patrick Chaftari, Aswin Srinivasan, Cielito C Reyes-Gibby
Förderung
- NCI NIH HHS
- The University of Texas MD Anderson Cancer Center
- NIH HHS
- National Institutes of Health (NIH)
- National Institutes of Health through MD Anderson’s Cancer Center
Zitieren
APA
Lipe, D. N., Qdaisat, A., Krishnamani, P. P., Nguyen, T. D., Chaftari, P., El Messiri, N., Srinivasan, A., Galvis-Carvajal, E., Reyes-Gibby, C. C., & Wattana, M. K. (2024). Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review. Diagnostics, 14(16), 1794. https://doi.org/10.3390/diagnostics14161794
Vancouver
Lipe DN, Qdaisat A, Krishnamani PP, Nguyen TD, Chaftari P, El Messiri N, et al. Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review. Diagnostics. 2024;14(16):1794. doi:10.3390/diagnostics14161794
BibTeX
@article{Lipe2024,
author = {Lipe, Demis N and Qdaisat, Aiham and Krishnamani, Pavitra P and Nguyen, Trung D and Chaftari, Patrick and El Messiri, Nour and Srinivasan, Aswin and Galvis-Carvajal, Elkin and Reyes-Gibby, Cielito C and Wattana, Monica K},
title = {Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {16},
pages = {1794},
doi = {10.3390/diagnostics14161794}
}
EUVIMED